Search

Your search keyword '"Armstrong, Paul W."' showing total 3,081 results
Start Over Author "Armstrong, Paul W."
3,081 results on '"Armstrong, Paul W."'

61. Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial)

Author

Metra, Marco, Mentz, Robert J., Hernandez, Adrian F., Heizer, Gretchen M., Armstrong, Paul W., Clausell, Nadine, Corbalan, Ramon, Costanzo, Maria Rosa, Dickstein, Kenneth, Dunlap, Mark E., Ezekowitz, Justin A., Howlett, Jonathan G., Komajda, Michel, Krum, Henry, Lombardi, Carlo, Fonarow, Gregg C., McMurray, John J.V., Nieminen, Markku S., Swedberg, Karl, Voors, Adriaan A., Starling, Randall C., Teerlink, John R., and O'Connor, Christopher M.

Published
2016
Full Text
View/download PDF

63. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

Author

Lincoff, A Michael, Mehran, Roxana, Povsic, Thomas J, Zelenkofske, Steven L, Huang, Zhen, Armstrong, Paul W, Steg, P Gabriel, Bode, Christoph, Cohen, Mauricio G, Buller, Christopher, Laanmets, Peep, Valgimigli, Marco, Marandi, Toomas, Fridrich, Viliam, Cantor, Warren J, Merkely, Bela, Lopez-Sendon, Jose, Cornel, Jan H, Kasprzak, Jaroslaw D, Aschermann, Michael, Guetta, Victor, Morais, Joao, Sinnaeve, Peter R, Huber, Kurt, Stables, Rod, Sellers, Mary Ann, Borgman, Marilyn, Glenn, Lauren, Levinson, Arnold I, Lopes, Renato D, Hasselblad, Vic, Becker, Richard C, and Alexander, John H

Published
2016
Full Text
View/download PDF

66. Rationale and Design of the VITALITY-HFpEF Trial

Author

Butler, Javed, Lam, Carolyn S.P., Anstrom, Kevin J., Ezekowitz, Justin, Hernandez, Adrian F., O’Connor, Christopher M., Pieske, Burkert, Ponikowski, Piotr, Shah, Sanjiv J., Solomon, Scott D., Voors, Adriaan A., Wu, Yi, Carvalho, Francine, Bamber, Luke, Blaustein, Robert O., Roessig, Lothar, and Armstrong, Paul W.

Published
2019
Full Text
View/download PDF

69. Relationship between baseline electrocardiographic measurements and outcomes in patients with high‐risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial.

Author

Yogasundaram, Haran, Zheng, Yinggan, Ly, Eric, Ezekowitz, Justin, Ponikowski, Piotr, Lam, Carolyn S.P., O'Connor, Christopher, Blaustein, Robert O., Roessig, Lothar, Temple, Tracy, Westerhout, Cynthia M., Armstrong, Paul W., and Sandhu, Roopinder K.

Subjects
BRAIN natriuretic factor, HEART failure, HEART failure patients, VENTRICULAR ejection fraction, RIGHT ventricular hypertrophy
Abstract

Aims: Whether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown. Methods and results: We studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12‐lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta‐Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N‐terminal pro‐B‐type natriuretic peptide, and index event. Select interactions between ECG measurements, patient characteristics and mortality were examined. Over a median of 10.8 months, there were 824 cardiovascular (CV) deaths (214 sudden) and 1005 all‐cause deaths. Median age was 68 years (interquartile range [IQR] 60–76), 24% were women, median ejection fraction was 30% (IQR 23–35), 41% had New York Heart Association class III/IV, and median MAGGIC score was 24 (IQR 19–28). After multivariable adjustment, significant associations existed between heart rate (per 5 bpm: HR 1.02), QRS duration (per 10 ms: HR 1.02), absence of left ventricular hypertrophy (HR 0.64) and CV death, and similarly so with all‐cause death (HR 1.02; HR 1.02; HR 0.61, respectively). Contiguous pathologic Q waves were significantly associated with sudden death (HR 1.46), and right ventricular hypertrophy with all‐cause death (HR 1.44). The only sex‐based interaction observed was for pathologic Q waves on CV (men: HR 1.05; women: HR 1.64, pinteraction = 0.024) and all‐cause death (men: HR 0.99; women: HR 1.57; pinteraction = 0.010). Whereas sudden death doubled in females, it did not differ among males (male: HR 1.25, 95% confidence interval [CI] 0.87–1.79; female: HR 2.50, 95% CI 1.23–5.06; pinteraction = 0.141). Conclusion: Routine ECG measurements provide additional prognostication of mortality in high‐risk HFrEF patients, particularly in women with contiguous pathologic Q waves. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

71. Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)

Author

Grodin, Justin L., Perez, Antonio L., Wu, Yuping, Hernandez, Adrian F., Butler, Javed, Metra, Marco, Felker, G. Michael, Voors, Adriaan A., McMurray, John J., Armstrong, Paul W., Califf, Robert M., Starling, Randall C., O'Connor, Christopher M., and Tang, W.H. Wilson

Published
2015
Full Text
View/download PDF

73. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)

Author

Cornel, Jan H., Tricoci, Pierluigi, Lokhnygina, Yuliya, Moliterno, David J., Wallentin, Lars, Armstrong, Paul W., Aylward, Philip E., Clare, Robert M., Chen, Edmond, Leonardi, Sergio, Van de Werf, Frans, White, Harvey D., Held, Claes, Strony, John, Mahaffey, Kenneth W., and Harrington, Robert A.

Published
2015
Full Text
View/download PDF

74. Relationship Between Time to Invasive Assessment and Clinical Outcomes of Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation Myocardial Infarction: A Patient-Level Analysis of the Randomized Early Routine Invasive Clinical Trials

Author

Madan, Mina, Halvorsen, Sigrun, Di Mario, Carlo, Tan, Mary, Westerhout, Cynthia M., Cantor, Warren J., Le May, Michel R., Borgia, Francesco, Piscione, Federico, Scheller, Bruno, Armstrong, Paul W., Fernandez-Aviles, Francisco, Sanchez, Pedro L., Graham, John J., Yan, Andrew T., and Goodman, Shaun G.

Published
2015
Full Text
View/download PDF

76. Editorial October 2024.

Author

Hughes, Belinda C and Armstrong, Paul W

Subjects
*EDUCATIONAL leadership, *TEACHERS, *EMPLOYEE motivation, *PROFESSIONS, *PRIMARY school teachers
Abstract

The latest issue of Management in Education features five articles that explore various challenges faced by teachers, leaders, and professionals in their work. One article focuses on the role of principal leadership in supporting distance learning during the pandemic in Greece, highlighting the importance of e-leadership. Another article discusses the significance of emotional intelligence in higher education institutes, emphasizing its impact on team members' mental health. A study conducted in Vietnam calls for teachers to develop their research capabilities to support the new general education curriculum. Additionally, an article examines the challenges faced by women in educational leadership in South Africa, calling for a deeper understanding of their experiences. Lastly, an opinion piece discusses affordable private schools in India and the need for policies to address inequalities in the education system. [Extracted from the article]

Published
2024
Full Text
View/download PDF

79. Outcomes of a Pharmacoinvasive Strategy for Successful Versus Failed Fibrinolysis and Primary Percutaneous Intervention in Acute Myocardial Infarction (from the Strategic Reperfusion Early After Myocardial Infarction [STREAM] Study)

Author

Welsh, Robert C., Van de Werf, Frans, Westerhout, Cynthia M., Goldstein, Patrick, Gershlick, Anthony H., Wilcox, Robert G., Danays, Thierry, Bluhmki, Erich, Lopes, Renato D., Steg, Philippe Gabriel, and Armstrong, Paul W.

Published
2014
Full Text
View/download PDF

80. Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)

Author

Valgimigli, Marco, Tricoci, Pierluigi, Huang, Zhen, Aylward, Philip E., Armstrong, Paul W., Van de Werf, Frans, Leonardi, Sergio, White, Harvey D., Widimsky, Petr, Harrington, Robert A., Cequier, Angel, Chen, Edmond, Lokhnygina, Yuliya, Wallentin, Lars, Strony, John, Mahaffey, Kenneth W., and Moliterno, David J.

Published
2014
Full Text
View/download PDF

82. Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)

Author

Mahaffey, Kenneth W., Huang, Zhen, Wallentin, Lars, Storey, Robert F., Jennings, Lisa K., Tricoci, Pierluigi, White, Harvey D., Armstrong, Paul W., Aylward, Philip E., Moliterno, David J., Van de Werf, Frans, Chen, Edmond, Leonardi, Sergio, Rorick, Tyrus, Held, Claes, Strony, John, and Harrington, Robert A.

Published
2014
Full Text
View/download PDF

88. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Author

Guimarães, Patrícia O., Leonardi, Sergio, Huang, Zhen, Wallentin, Lars, Van de Werf, Frans, Aylward, Philip E., Held, Claes, Harrington, Robert A., Moliterno, David J., Armstrong, Paul W., White, Harvey D., Alexander, Karen P., Lopes, Renato D., Mahaffey, Kenneth W., and Tricoci, Pierluigi

Published
2018
Full Text
View/download PDF

97. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.

Author

Pieske, Burkert, Pieske‐Kraigher, Elisabeth, Lam, Carolyn S.P., Melenovský, Vojtěch, Sliwa, Karen, Lopatin, Yuri, Arango, Juan Luis, Bahit, M. Cecilia, O'Connor, Christopher M., Patel, Mahesh J., Roessig, Lothar, Morris, Daniel A., Kropf, Martin, Westerhout, Cynthia M., Zheng, Yinggan, and Armstrong, Paul W.

Subjects
HEART failure patients, VENTRICULAR ejection fraction, ECHOCARDIOGRAPHY, HEART failure, CARDIOVASCULAR disease related mortality
Abstract

Aim: Vericiguat significantly reduced the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death in the VICTORIA trial. It is unknown if these outcome benefits are related to reverse left ventricular (LV) remodelling with vericiguat in patients with HF with reduced ejection fraction (HFrEF). The aim of this study was to compare the effects of vericiguat versus placebo on LV structure and function after 8 months of therapy in patients with HFrEF. Methods and results: Standardized transthoracic echocardiography (TTE) was performed at baseline and after 8 months of therapy in a subset of HFrEF patients in VICTORIA. The co‐primary endpoints were changes in LV end‐systolic volume index (LVESVI) and LV ejection fraction (LVEF). Quality assurance and central reading were performed by an echocardiographic core laboratory blinded to treatment assignment. A total of 419 patients (208 vericiguat, 211 placebo) with high‐quality paired TTE at baseline and 8 months were included. Baseline clinical characteristics were well balanced between treatment groups and echocardiographic characteristics were representative of patients with HFrEF. LVESVI significantly declined (60.7 ± 26.8 to 56.8 ± 30.4 ml/m2; p < 0.01) and LVEF significantly increased (33.0 ± 9.4% to 36.1 ± 10.2%; p < 0.01) in the vericiguat group, but similarly in the placebo group (absolute changes for vericiguat vs. placebo: LVESVI −3.8 ± 15.4 vs. −7.1 ± 20.5 ml/m2; p = 0.07 and LVEF +3.2 ± 8.0% vs. +2.4 ± 7.6%; p = 0.31). The absolute rate per 100 patient‐years of the primary composite endpoint at 8 months tended to be lower in the vericiguat group (19.8) than the placebo group (29.6) (p = 0.07). Conclusions: In this pre‐specified echocardiographic study, significant improvements in LV structure and function occurred over 8 months in both vericiguat and placebo in a high‐risk HFrEF population with recent worsening HF. Further studies are warranted to define the mechanisms of vericiguat's benefit in HFrEF. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

100. Finding the right balance between precision medicine and personalized care

Author

McAlister, Finlay A., Laupacis, Andreas, and Armstrong, Paul W.

Subjects
Precision medicine -- Usage -- Comparative analysis -- Health aspects, Evidence-based medicine -- Comparative analysis -- Health aspects, Patient compliance -- Analysis, Health
Abstract

The term precision medicine refers to the tailoring of diagnostics or therapeutics to individual patients based on their unique genetic and physiologic characteristics. (1) Although 'personalized or individualized care' (i.e., [...]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results